

A4 Sub B2
9. (Amended) A method of reducing the risk of a subject becoming infected with a sexually transmitted pathogen, the method comprising contacting the pathogen or cells susceptible to infection by the pathogen in the subject with a pharmaceutical composition consisting essentially of a β -cyclodextrin, thereby reducing the risk of the subject becoming infected with the sexually transmitted pathogen.

A5
13. (Amended) The method of claim 8, wherein the pharmaceutical composition is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, a lubricant, a jelly, or a spray.

14. (Amended) The method of claim 9, wherein the pharmaceutical composition is formulated in a suppository, a film, a vaginal disk, a bioadhesive polymer, a sponge, a diaphragm, a glove, a tampon, a pellet, a tablet, or a condom.

A6
20. (Amended) The method of claim 19, wherein the enveloped virus is an immunodeficiency virus, a T lymphotropic virus, a herpes virus, a measles virus, or an influenza virus.

A7 Sub B2
23. (Amended) A method of reducing the risk of transmission of a sexually transmitted disease by a subject infected with a sexually transmitted pathogen, the method comprising contacting the pathogen or cells susceptible to infection by the pathogen with a pharmaceutical composition consisting essentially of a β -cyclodextrin, thereby reducing the risk of transmission of the sexually transmitted disease by the subject.

A⁸
28. (Amended) The method of claim 23, wherein the pharmaceutical composition is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, a lubricant, a jelly, or a spray.

29. (Amended) The method of claim 23, wherein the pharmaceutical composition is formulated in a suppository, a bioadhesive polymer, a vaginal disk, a film, a diaphragm, a glove, a tampon, a pellet, a tablet, or a condom.

A⁹
34. (Amended) The method of claim 33, wherein the enveloped virus is an immunodeficiency virus, a T lymphotropic virus, a herpes virus, a measles virus, or an influenza virus.

~~A¹⁰ Sub B¹~~
~~37. (Amended) A pharmaceutical composition, consisting essentially of a β -cyclodextrin.~~

~~A¹¹ Sub B²~~
~~40. (Amended) A composition for reducing the risk of transmission of a sexually transmitted disease, the composition consisting essentially of a solid substrate and a β -cyclodextrin.~~

Please add the following new claims:

A¹²
--46. The pharmaceutical composition of claim 37, which is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, a lubricant, a jelly, or a spray.

47. The pharmaceutical composition of claim 37, which is formulated in a suppository, a film, a sponge, a condom, a bioadhesive polymer, a diaphragm, a glove, a pellet, a tablet, or a tampon.

In re Application of
James E. Hildreth
Application No.: 09/802,779
Filed: March 8, 2001
Page 5

PATENT
Attorney Docket No.: JHU1710-3

48. The pharmaceutical composition of claim 37, wherein the β -cyclodextrin is in a concentration of 1 mM to 100 mM.

49. The pharmaceutical composition of claim 37, wherein the β -cyclodextrin is in a concentration of 5 mM to 30 mM.

50. The composition of claim 40, wherein the β -cyclodextrin is present in an amount of 0.1 grams to 2 grams.

51. The composition of claim 40, wherein the β -cyclodextrin is present in an amount of 0.25 grams to 0.75 grams.--
